» Related Searches: cancer, lung cancer treatment, prostate cancer, lung, breast cancer

… cancer prognosis, a Mayo Clinic review and analysis of existing lung cancer
studies shows that this technology has not yet surpassed the accuracy of conventional
methods used to assess survival … 
* Amrubicin approved and marketed in Japan for lung cancer * Pharmion to initiate
registration study in US and EU for SCLC in 2H 2007 * NDA and MAA submissions anticipated
in 2009 … 
Allen Carr, 73, is the author of numerous books on how to quit smoking. He was diagnosed
with lung cancer in July this year … 
Pharmion Corporation has purchased private oncology company Cabrellis, which holds the US
and EU rights to lung cancer drug amrubicin, for $59 million … 
… lung cancer by 20 to 30 percent. The findings also suggest that it really does
not take a great deal of exposure to this smoke for it to begin taking … 
… lung cancer. The deal was worth $59M, along with two additional payments of
$12.... (more) … 
It's been more than a year since Peter Jennings died of lung cancer — and since
another newsman, Mike Taibbi, smoked his final cigarette … 
… lung cancer in an established mouse model of the disease. This data, produced in
the laboratory of Dr. [click link for full article] … 
Reata Pharmaceuticals has presented preclinical data showing that its investigatonal drug
candidate RTA 402 prevented the development of lung cancer in a mouse model of the
disease … 
… lung cancer as a result of exposure, according to the Radiological Protection
Institute of Ireland (RPII) … 